Fractyl Health Reports Revita Procedure Sustains Weight Loss Six Months After GLP-1 Discontinuation
Reuters
Yesterday
<a href="https://laohu8.com/S/GUTS">Fractyl Health</a> Reports Revita Procedure Sustains Weight Loss Six Months After GLP-1 Discontinuation
Fractyl Health Inc. has announced positive 6-month results from its open-label REVEAL-1 Cohort study. The study involved individuals with obesity who had lost at least 15% of their total body weight on a GLP-1 medication and had either discontinued or needed to discontinue GLP-1 therapy. Participants who underwent a single Revita procedure after stopping GLP-1 therapy maintained stable body weight and glycemic control over six months. The company also reported a 1.5% mean weight change among the 17 participants, compared to approximately 10% weight regain typically observed in similar patients who discontinue GLP-1 therapy without further intervention. Upcoming randomized 6-month data from the REMAIN-1 Midpoint Cohort are expected in January 2026, with additional clinical readouts and a potential Premarket Approval (PMA) filing for Revita anticipated in the second half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594949-en) on December 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.